Key US Entresto Barriers Are PA Process & Co-Payments – BMT Poll

A BioMedTracker poll canvassing 23 US-based cardiologists about the main clinical and reimbursement hurdles causing the slow uptake there of Novartis's heart failure drug Entresto (valsartan/sacubitril) suggests insurance issues - namely pre-authorization and high co-payments - are the key causes. More than a third of respondents also listed reluctance to switch patients doing well on current medications, while only 9-13% listed lack of confidence about efficacy, concerns about hypotension, or titration issues as important barriers.

These were the main takeaways from replies by cardiologists to questions about the major barriers preventing use of Entresto in Class II-IV heart failure patients with reduced ejection fraction (HFrEF),...